REG - Genflow Biosciences - Institutional Investment

Genflow BiosciencesAnnouncement

26/03/2025 07:16

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ1473Ca&default-theme=true

RNS Number : 1473C  Genflow Biosciences PLC  26 March 2025

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

26 March 2025

 

Genflow Biosciences Plc

 

Genflow Secures £434,083 from a Leading Institution and Launches a Gene
Therapy Trial in Aged Dogs

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company")
the only longevity company listed in Europe, is pleased to announce it has
received a binding offer from a major institution for an equity investment
totalling £434,083 (before expenses).

 

The investor has applied for 41,341,324 Ordinary Shares of £0.0003 each at a
price of 1.05p (the "New Ordinary Shares"). The number of New Ordinary Shares
applied for by the subscriber is the maximum number of shares (on a fully
diluted basis) available to the Company to issue without the need to produce a
Prospectus. These New Ordinary Shares cannot be issued until after 9 April
2025 when the Company's headroom, under the Prospectus Rules, increases.

 

An application will be made to the Main Market of the London Stock Exchange,
and admission of the New Ordinary Shares to trading is expected on or around
10 April 2025 ("Admission"). The New Ordinary Shares will, when issued,
rank pari passu with the Company's existing Ordinary Shares.

 

Director's Intended Participation

 

Eric Leire, a Director of the Company, intends to invest £50,000 on the same
terms as the investment outlined above on the basis that such participation
falls under the employee offer exemption under Article 1(4)(i) and 1(5)(h) of
the UK Prospectus Regulation, and further, subject to the Company not being in
a Closed Period at the time of such investment and the same being subject to
the Company's share dealing policy.

 

A further announcement will be made in relation to this in due course.

 

Total Voting Rights

 

For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
391,047,942 ordinary shares. For the avoidance of doubt, this excludes any
intended equity participation by Eric Leire.

 

The Company does not hold any shares in treasury. The above figure may be used
by Shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company, under the Disclosure Guidance and Transparency
Rules.

 

Tamara Joseph, Chair of the Company, commented "We are extremely pleased to
have been approached by an institution who wishes to support Genflow in its
journey in pioneering gene therapies to decelerate the aging process. The use
of these proceeds will accelerate the Company's proposed studies and trials in
aged dogs, an issue which has attracted a great deal of press coverage,
including in recent weeks."

 

Use of Proceeds

 

This investment, combined with previously awarded government grants, will
accelerate the Company's planned 2025 programs including launching a clinical
trial in aged dogs.

 

Genflow has commenced a proof-of-concept clinical trial to evaluate the safety
and efficacy of its proprietary SIRT6-centenarian gene therapy targeting
age-related decline in dogs.

 

The Company will treat the dogs for 6 months and assess the safety and
efficacy of our therapy for the following 6 months. This is a randomized,
controlled trial with 28 dogs aged 10+ years, conducted with the renowned CRO,
Syngene.  Genflow will compare recipient dogs of intravenous injections of
proprietary SIRT6 gene therapy versus untreated control group.  Endpoints
will include biological age estimation (via GRIM methylation clock), muscle
strength, muscle mass, mitochondrial function, coat quality and overall health
indicators.

 

"As a devoted dog owner myself, I have a 9-year-old golden retriever, I know
firsthand the desire we all share for more happy, healthy years of with our
beloved pets," said Dr. Eric Leire, CEO of Genflow. "Our goal is not just to
extend their lifespan, but to enhance their quality of life. By targeting
biological aging in dogs, we also can unlock groundbreaking insights that
could revolutionize both veterinary and human medicine. This research has the
potential to reshape the way we approach aging, offering hope for longer,
healthier lives for all."

 

Further updates on the progress of the study will be provided in due course.

 

Contacts

 

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Corporate Broker
 Capital Plus Partners Ltd
 Jon Critchley, +44 0203 821 6168

 

 

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Expected to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn and Twitter/X.

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEFEFIEISEDD